サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1421682

神経バイオマーカー市場、シェア、規模、動向、産業分析レポート：タイプ別、用途別、最終用途別、地域別、セグメント別予測、2024年～2032年

Neurological Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Metabolomic, Genomic, Imaging, Proteomic, Others); By Application; By End-Use; By Region; Segment Forecast, 2024 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
神経バイオマーカー市場、シェア、規模、動向、産業分析レポート：タイプ別、用途別、最終用途別、地域別、セグメント別予測、2024年～2032年
出版日: 2023年11月23日
発行: Polaris Market Research
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の神経バイオマーカー市場規模は2032年までに248億3,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

神経バイオマーカーは、症状を測定・評価したり、特定の治療に対する薬理学的反応を判定したりするための指標として機能します。自閉症、パーキンソン病、うつ病など、さまざまな疾患の診断に幅広く応用されています。これらのバイオマーカーは、メタボロミクス、イメージング、ゲノミクス、プロテオミクスなど、いくつかのカテゴリーに分類されます。

シグネチャーバイオマーカーを含む神経バイオマーカーの進歩は、神経疾患の治療効果を高め、医薬品開発を促進し、早期診断を可能にし、非侵襲的検査を容易にしています。さらに、デジタルバイオマーカーは製薬会社に貴重な補足情報を提供し、臨床試験の意思決定を助け、結果として神経バイオマーカー市場の成長を促進しています。

個別化医療の領域では、神経変性疾患の神経バイオマーカー調査が急速に進展しており、さまざまな神経変性疾患との関連や評価が多数の分子で行われています。このような精密医療の進化は、バイオ医薬品業界に大きな影響を与えており、バイオ医薬品会社から診断薬会社まで、商業的事業から研究開発まで、さまざまなプレーヤーに大きな変革をもたらしつつあります。

しかし、バイオマーカー開発サイクルの長期化や立ち上げコストの増大により、市場の成長は妨げられる可能性があります。ポジティブな点としては、様々な研究段階で資金を提供する機関が存在するため、市場拡大のチャンスは十分にあります。特に、米国国立衛生研究所（NIH）は、アルツハイマー病と脳の老化における健康格差に関連する研究を支援するために追加資金を割り当てており、市場の成長をさらに刺激しています。

さらに、2021年6月にNational Library of Medicineに掲載された研究では、冠動脈疾患（CAD）が世界の健康に与える影響の大きさが強調されました。CADだけで年間約61万人が死亡しており、推定死亡者数の4人に1人を占め、米国における死亡原因の第1位となっています。CADの発症率が上昇するにつれ、この差し迫った医療ニーズに対処するための効果的な神経バイオマーカー装置に対する需要が高まっています。その結果、この要因が予測期間を通じて神経バイオマーカーの需要を促進すると予測されています。

神経バイオマーカー市場レポートハイライト

  • 2022年、プロテオミクス分野が最も高い収益シェアを獲得プロテオミクスバイオマーカーは、特にmRNA発現だけに頼っていては多様な翻訳後修飾の機能的意味を明らかにできない場合に、極めて重要な役割を果たします。このような状況において、プロテオミクスバイオマーカーは、タンパク質のシグネチャーと翻訳後修飾の変化を綿密に検出することにより、疾患の発症と進行を正確に診断するために不可欠なものとなります。これらのバイオマーカーは、アルツハイマー病（AD）のような複雑で説明のつかない病態の根底にある細胞の変化を明らかにする上で、顕著な有効性を示しています。ADの顕著なプロテオミクスバイオマーカーとしては、グリア線維酸性タンパク質（GFAP）、銅-亜鉛スーパーオキシドジスムターゼ（SOD1）、AB42、タウ、ABペプチドなどがあります。新製品の継続的なイントロダクションが市場成長の原動力になると予想されます。
  • アルツハイマー病は2022年に最大の市場シェアを確保し、予測期間中もその優位性が続くと予想されます。この動向は主に、この疾患の有病率の上昇と、早期診断と迅速な治療への注目の高まりによるものです。
  • 2022年には、北米が最大市場として主導権を握った。北米の神経バイオマーカー市場は大きなシェアを占めており、今後の予測期間には注目すべきCAGRを示すと予想されています。この成長は、神経疾患の有病率の高さや、この分野の支援を目的とした政府のイニシアティブの急増など、いくつかの要因に支えられています。さらに、同市場は新製品の上市やバイオマーカー需要の増加からも利益を得ようとしています。同地域では、研究および革新的バイオマーカー開発のための資金援助が活発に行われており、市場の拡大にさらに貢献しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の神経バイオマーカー市場に関する洞察

  • 神経バイオマーカー市場- 用途スナップショット
  • 神経バイオマーカー市場力学
    • 促進要因と機会
      • 神経疾患の発生率の増加
      • バイオマーカーの研究開発（R&D）への投資の増加
    • 抑制要因と課題
      • 初期投資費用が高く、バイオマーカー開発サイクルが長い
  • PESTEL分析
  • 神経バイオマーカー市場応用動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の神経バイオマーカー市場、タイプ別

  • 主な調査結果
  • イントロダクション
  • メタボロミクス
  • ゲノム
  • イメージング
  • プロテオミクス
  • その他

第6章 世界の神経バイオマーカー市場、最終用途別

  • 主な調査結果
  • イントロダクション
  • 独立臨床診断センター
  • 研究機関等
  • 病院および病院検査室

第7章 世界の神経バイオマーカー市場、用途別

  • 主な調査結果
  • イントロダクション
  • 自閉症スペクトラム障害
  • パーキンソン病
  • アルツハイマー病
  • 多発性硬化症
  • その他

第8章 世界の神経バイオマーカー市場、地域別

  • 主な調査結果
  • イントロダクション
    • 神経バイオマーカー市場評価、地域、2019-2032年
  • 神経バイオマーカー市場-北米
    • 北米：神経バイオマーカー市場、タイプ別、2019-2032年
    • 北米：神経バイオマーカー市場、用途別、2019-2032年
    • 北米：神経バイオマーカー市場、最終用途別、2019-2032年
    • 神経バイオマーカー市場-米国
    • 神経バイオマーカー市場- カナダ
  • 神経バイオマーカー市場- 欧州
    • 欧州：神経バイオマーカー市場、タイプ別、2019～2032年
    • 欧州：神経バイオマーカー市場、用途別、2019～2032年
    • 欧州：神経バイオマーカー市場、最終用途別、2019～2032年
    • 神経バイオマーカー市場- 英国
    • 神経バイオマーカー市場- フランス
    • 神経バイオマーカー市場- ドイツ
    • 神経バイオマーカー市場- イタリア
    • 神経バイオマーカー市場- スペイン
    • 神経バイオマーカー市場- オランダ
    • 神経バイオマーカー市場- ロシア
  • 神経バイオマーカー市場- アジア太平洋
    • アジア太平洋：神経バイオマーカー市場、タイプ別、2019～2032年
    • アジア太平洋：神経バイオマーカー市場、用途別、2019～2032年
    • アジア太平洋：神経バイオマーカー市場、最終用途別、2019～2032年
    • 神経バイオマーカー市場- 中国
    • 神経バイオマーカー市場- インド
    • 神経バイオマーカー市場- マレーシア
    • 神経バイオマーカー市場- 日本
    • 神経バイオマーカー市場- インドネシア
    • 神経バイオマーカー市場- 韓国
  • 神経バイオマーカー市場-中東およびアフリカ
    • 中東およびアフリカ：神経バイオマーカー市場、タイプ別、2019～2032年
    • 中東およびアフリカ：神経バイオマーカー市場、用途別、2019～2032年
    • 中東およびアフリカ：神経バイオマーカー市場、最終用途別、2019～2032年
    • 神経バイオマーカー市場- サウジアラビア
    • 神経バイオマーカー市場- アラブ首長国連邦
    • 神経バイオマーカー市場- イスラエル
    • 神経バイオマーカー市場- 南アフリカ
  • 神経バイオマーカー市場-ラテンアメリカ
    • ラテンアメリカ：神経バイオマーカー市場、タイプ別、2019-2032年
    • ラテンアメリカ：神経バイオマーカー市場、用途別、2019-2032年
    • ラテンアメリカ：神経バイオマーカー市場、最終用途別、2019-2032年
    • 神経バイオマーカー市場- メキシコ
    • 神経バイオマーカー市場- ブラジル
    • 神経バイオマーカー市場- アルゼンチン

第9章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • Abbott
  • Alseres Pharmaceuticals, Inc.
  • BANYAN BIOMARKERS, INC.
  • Bio-Rad Laboratories, Inc.
  • DiaGenic ASA
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Quanterix
  • Thermo Fisher Scientific, Inc.
図表

List of Tables

  • Table 1 Global Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 3 Global Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 4 Neurological Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 7 North America: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 8 U.S.: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 10 U.S.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 11 Canada: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 13 Canada: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 14 Europe: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 16 Europe: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 17 UK: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 19 UK: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 20 France: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 22 France: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 23 Germany: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 25 Germany: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 26 Italy: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 28 Italy: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 29 Spain: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 31 Spain: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 35 Russia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 37 Russia: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 41 China: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 43 China: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 44 India: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 46 India: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 50 Japan: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 52 Japan: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 56 South Korea: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 58 South Korea: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 65 UAE: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 67 UAE: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 68 Israel: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 70 Israel: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 71 South Africa: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 73 South Africa: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 74 Latin America: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 76 Latin America: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 77 Mexico: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 79 Mexico: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 80 Brazil: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 82 Brazil: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • Table 83 Argentina: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • Table 85 Argentina: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Neurological Biomarkers Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by End Use
  • Figure 7. Global Neurological Biomarkers Market, by End Use, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Neurological Biomarkers Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Application
  • Figure 11. Global Neurological Biomarkers Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 12. Neurological Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Neurological Biomarkers Market
目次
Product Code: PM4022

The global neurological biomarkers market size is expected to reach USD 24.83 billion by 2032, according to a new study by Polaris Market Research. The report "Neurological Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Metabolomic, Genomic, Imaging, Proteomic, Others); By Application; By End-Use; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Neurological biomarkers serve as indicators for measuring and assessing symptoms or determining a pharmacological response to a specific treatment. They find extensive application in the diagnosis of various conditions, including autism, Parkinson's disease, and depression. These biomarkers fall into several categories, including metabolomics, imaging, genomics, and proteomics.

Advancements in neurological biomarkers, encompassing signature biomarkers, are enhancing the effectiveness of treating neurological diseases, expediting drug development, enabling early diagnosis, and facilitating noninvasive testing. Furthermore, digital biomarkers are supplying valuable supplementary information to pharmaceutical companies, aiding in clinical trial decision-making and, consequently, propelling the growth of the neurological biomarkers market.

In the realm of personalized medicine, neurological biomarker research for neurodegenerative diseases represents a rapidly advancing field, with numerous molecules being associated and evaluated in the context of various neurodegenerative disorders. This evolution in precision medicine is significantly influencing the biopharmaceutical industry, leading to substantial transformations across various players, from biopharma to diagnostics companies, with roles ranging from commercial operations to research and development.

Even with this, the market's growth may be hindered by protracted biomarker development cycles and substantial startup costs. On a positive note, the presence of organizations offering funding at various research stages presents ample opportunities for market expansion. Notably, the National Institutes of Health (NIH) is allocating additional funds to support research related to health disparities in Alzheimer's and brain aging, further stimulating market growth.

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective Neurological Biomarkers devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for Neurological Biomarkers throughout the forecast period.

Neurological Biomarkers Market Report Highlights

  • In 2022, the Proteomic segment dominated with the highest revenue share. Proteomic biomarkers play a pivotal role, especially when relying solely on mRNA expression falls short in revealing the functional implications of diverse post-translational modifications. In such scenarios, proteomic biomarkers become indispensable for accurately diagnosing the onset and progression of diseases by meticulously detecting protein signatures and post-translational changes. These biomarkers have demonstrated remarkable effectiveness in unveiling the cellular alterations underlying complex and unexplained conditions like Alzheimer's disease (AD). Prominent proteomic biomarkers for AD include glial fibrillary acidic protein (GFAP), copper-zinc superoxide dismutase (SOD1), AB42, tau, and AB peptides. The continuous introduction of new products is expected to be a driving force behind market growth.
  • Alzheimer's disease secured the largest market share in 2022 and is expected to continue its dominance during the forecast period. This trend is mainly driven by the rising prevalence of the disease and a heightened focus on early diagnosis and prompt treatment.
  • In 2022, North America took the lead as the largest market. The neurological biomarkers market in North America holds a substantial share and is expected to exhibit a noteworthy CAGR in the upcoming forecast period. This growth is underpinned by several factors, including the high prevalence of neurological disorders and the surge in government initiatives aimed at supporting this sector. Moreover, the market is set to gain from a growing influx of new product launches and an increasing demand for biomarkers. The region maintains robust funding for research and the development of innovative biomarkers, further contributing to market advancement.
  • The global key market players include: Abbott, Alseres Pharmaceuticals, Inc., BANYAN BIOMARKERS, INC., Bio-Rad Laboratories, Inc., DiaGenic ASA, Johnson & Johnson Services, Inc., Merck & Co., Inc., Myriad Genetics, Inc., Quanterix, Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the Neurological Biomarkers market report based on type, application, end-use, and region:

Neurological Biomarkers, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Metabolomic
  • Genomic
  • Imaging
  • Proteomic
  • Others

Neurological Biomarkers, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Autism Spectrum Disorder
  • Parkinson's Disease
  • Alzheimer's Disease
  • Multiple Sclerosis
  • Others

Neurological Biomarkers, End-Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Independent clinical diagnostic centers
  • Research Organizations and Others
  • Hospital & Hospital Laboratories

Neurological Biomarkers, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Neurological Biomarkers Market Insights

  • 4.1. Neurological Biomarkers Market - Application Snapshot
  • 4.2. Neurological Biomarkers Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Incidence of Neurological Disorders
      • 4.2.1.2. Elevated investment in Research and Development (R&D) for biomarkers
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High initial investment expenses and lengthy biomarker development cycles
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Neurological Biomarkers Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Neurological Biomarkers Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Metabolomic
    • 5.3.1. Global Neurological Biomarkers Market, by Metabolomic, by Region, 2019-2032 (USD Billion)
  • 5.4. Genomic
    • 5.4.1. Global Neurological Biomarkers Market, by Genomic, by Region, 2019-2032 (USD Billion)
  • 5.5. Imaging
    • 5.5.1. Global Neurological Biomarkers Market, by Imaging, by Region, 2019-2032 (USD Billion)
  • 5.6. Proteomic
    • 5.6.1. Global Neurological Biomarkers Market, by Proteomic, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Neurological Biomarkers Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Neurological Biomarkers Market, by End Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 6.3.Independent clinical diagnostic centers
    • 6.3.1. Global Neurological Biomarkers Market, by Independent clinical diagnostic centers, by Region, 2019-2032 (USD Billion)
  • 6.4. Research Organizations and Others
    • 6.4.1. Global Neurological Biomarkers Market, by Research Organizations and Others, by Region, 2019-2032 (USD Billion)
  • 6.5. Hospital & Hospital Laboratories
    • 6.5.1. Global Neurological Biomarkers Market, by Hospital & Hospital Laboratories, by Region, 2019-2032 (USD Billion)

7. Global Neurological Biomarkers Market, by Application

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
  • 7.3. Autism Spectrum Disorder
    • 7.3.1. Global Neurological Biomarkers Market, by Autism Spectrum Disorder, By Region, 2019-2032 (USD Billion)
  • 7.4. Parkinson's Disease
    • 7.4.1. Global Neurological Biomarkers Market, by Parkinson's Disease, By Region, 2019-2032 (USD Billion)
  • 7.5. Alzheimer's Disease
    • 7.5.1. Global Neurological Biomarkers Market, by Alzheimer's Disease, By Region, 2019-2032 (USD Billion)
  • 7.6. Multiple Sclerosis
    • 7.6.1. Global Neurological Biomarkers Market, by Multiple Sclerosis, By Region, 2019-2032 (USD Billion)
  • 7.7. Others
    • 7.7.1. Global Neurological Biomarkers Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Neurological Biomarkers Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Neurological Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Neurological Biomarkers Market - North America
    • 8.3.1. North America: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.3.3. North America: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.3.4. Neurological Biomarkers Market - U.S.
      • 8.3.4.1. U.S.: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.3.5. Neurological Biomarkers Market - Canada
      • 8.3.5.1. Canada: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 8.4. Neurological Biomarkers Market - Europe
    • 8.4.1. Europe: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.4. Neurological Biomarkers Market - UK
      • 8.4.4.1. UK: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.5. Neurological Biomarkers Market - France
      • 8.4.5.1. France: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.6. Neurological Biomarkers Market - Germany
      • 8.4.6.1. Germany: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.7. Neurological Biomarkers Market - Italy
      • 8.4.7.1. Italy: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.8. Neurological Biomarkers Market - Spain
      • 8.4.8.1. Spain: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.9. Neurological Biomarkers Market - Netherlands
      • 8.4.9.1. Netherlands: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.4.10. Neurological Biomarkers Market - Russia
      • 8.4.10.1. Russia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 8.5. Neurological Biomarkers Market - Asia Pacific
    • 8.5.1. Asia Pacific: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.4. Neurological Biomarkers Market - China
      • 8.5.4.1. China: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.5. Neurological Biomarkers Market - India
      • 8.5.5.1. India: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.6. Neurological Biomarkers Market - Malaysia
      • 8.5.6.1. Malaysia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.7. Neurological Biomarkers Market - Japan
      • 8.5.7.1. Japan: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.8. Neurological Biomarkers Market - Indonesia
      • 8.5.8.1. Indonesia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.5.9. Neurological Biomarkers Market - South Korea
      • 8.5.9.1. South Korea: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 8.6. Neurological Biomarkers Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.4. Neurological Biomarkers Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.5. Neurological Biomarkers Market - UAE
      • 8.6.5.1. UAE: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.6. Neurological Biomarkers Market - Israel
      • 8.6.6.1. Israel: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.6.7. Neurological Biomarkers Market - South Africa
      • 8.6.7.1. South Africa: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
  • 8.7. Neurological Biomarkers Market - Latin America
    • 8.7.1. Latin America: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.4. Neurological Biomarkers Market - Mexico
      • 8.7.4.1. Mexico: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.5. Neurological Biomarkers Market - Brazil
      • 8.7.5.1. Brazil: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)
    • 8.7.6. Neurological Biomarkers Market - Argentina
      • 8.7.6.1. Argentina: Neurological Biomarkers Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Neurological Biomarkers Market, by Application, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Neurological Biomarkers Market, by End Use, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Alseres Pharmaceuticals, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. BANYAN BIOMARKERS, INC.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bio-Rad Laboratories, Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. DiaGenic ASA
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Johnson & Johnson Services, Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Merck & Co., Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Myriad Genetics, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Quanterix
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Thermo Fisher Scientific, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development